Leukocyte Ratio Investigated for Familial Mediterranean Fever Patients
By LabMedica International staff writers Posted on 28 Apr 2014 |

Image: Stained leukocytes in a peripheral blood smear (Photo courtesy of Dr. Kristine Krafts, MD).
Blood neutrophil-to-lymphocyte (N/L) ratio is a simple marker of inflammation that can be easily obtained from the differential leucocyte count and has been used to determine disease activity and diagnosis in patients with ulcerative colitis (UC) and acute appendicitis.
Familial Mediterranean Fever (FMF) is a recurrent, autosomal recessive autoinflammatory disease characterized with fever and serositis, which is accompanied by pain in the abdominal area, chest, and joints and the disease, is common among Mediterranean communities including Turks, Armenians, Jews, and Arabs.
Scientists at the Bozok University Medical School (Yozgat, Turkey) enrolled 115 patients and controls in the study. The cases in the study were categorized as FMF with attack, FMF with attack-free period, and controls. There were 79 patients with FMF and 36 control subjects. There were 29 females and 50 males in the FMF group and 12 females and 24 males in the control group. The data collected included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), total white blood cell count (WBC), neutrophil counts, lymphocyte counts, and number of platelets.
The median disease duration in FMF patients was 10 years and age and sex were similar in the FMF and control groups. The ESR was significantly higher in FMF patients during the attack phase. The CRP increased during attack but this was not statistically significant and WBC counts did not differ among groups. The mean N/L ratios of the controls was 1.63 (range: 1.41 to 2.33), for FMF patients who were attack- free the ratio was 1.83 (range 1.21 to 2.23), and for FMF patients during attack it was 2.95 (range: 1.91 to 3.46). The serum N/L ratios of FMF patients during attack were significantly higher than those of attack-free FMF patients and controls. While the serum neutrophil count increased in FMF patients during attack, in attack-free FMF patients and controls, the serum lymphocyte count did not differ.
The authors concluded that the N/L ratio, an indicator of the overall inflammatory status of the body, is higher in active FMF patients than in FMF patients in remission and healthy controls. A cut-off ratio value of 2.63 can be used to identify patients with active FMF. N/L ratio is not related with disease duration and inflammatory markers such as CRP and ESR in FMF patients. It is an inexpensive and readily available measure that could in combination with other markers help identify patients with active disease. The study was published on March 28, 2014, in the Journal of Clinical Laboratory Analysis.
Related Links:
Bozok University Medical School
Familial Mediterranean Fever (FMF) is a recurrent, autosomal recessive autoinflammatory disease characterized with fever and serositis, which is accompanied by pain in the abdominal area, chest, and joints and the disease, is common among Mediterranean communities including Turks, Armenians, Jews, and Arabs.
Scientists at the Bozok University Medical School (Yozgat, Turkey) enrolled 115 patients and controls in the study. The cases in the study were categorized as FMF with attack, FMF with attack-free period, and controls. There were 79 patients with FMF and 36 control subjects. There were 29 females and 50 males in the FMF group and 12 females and 24 males in the control group. The data collected included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), total white blood cell count (WBC), neutrophil counts, lymphocyte counts, and number of platelets.
The median disease duration in FMF patients was 10 years and age and sex were similar in the FMF and control groups. The ESR was significantly higher in FMF patients during the attack phase. The CRP increased during attack but this was not statistically significant and WBC counts did not differ among groups. The mean N/L ratios of the controls was 1.63 (range: 1.41 to 2.33), for FMF patients who were attack- free the ratio was 1.83 (range 1.21 to 2.23), and for FMF patients during attack it was 2.95 (range: 1.91 to 3.46). The serum N/L ratios of FMF patients during attack were significantly higher than those of attack-free FMF patients and controls. While the serum neutrophil count increased in FMF patients during attack, in attack-free FMF patients and controls, the serum lymphocyte count did not differ.
The authors concluded that the N/L ratio, an indicator of the overall inflammatory status of the body, is higher in active FMF patients than in FMF patients in remission and healthy controls. A cut-off ratio value of 2.63 can be used to identify patients with active FMF. N/L ratio is not related with disease duration and inflammatory markers such as CRP and ESR in FMF patients. It is an inexpensive and readily available measure that could in combination with other markers help identify patients with active disease. The study was published on March 28, 2014, in the Journal of Clinical Laboratory Analysis.
Related Links:
Bozok University Medical School
Latest Hematology News
- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
- WBC Count Could Predict Severity of COVID-19 Symptoms
- New Platelet Counting Technology to Help Labs Prevent Diagnosis Errors
- Streamlined Approach to Testing for Heparin-Induced Thrombocytopenia Improves Diagnostic Accuracy
- POC Hemostasis System Could Help Prevent Maternal Deaths
- New Test Assesses Oxygen Delivering Ability of Red Blood Cells by Measuring Their Shape
- Personalized CBC Testing Could Help Diagnose Early-Stage Diseases in Healthy Individuals
- Non-Invasive Test Solution Determines Fetal RhD Status from Maternal Plasma
- First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Channels
Clinical Chemistry
view channel
Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
Current sensors can measure various health indicators, such as blood glucose levels, in the body. However, there is a need to develop more accurate and sensitive sensor materials that can detect lower... Read more
Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
In regions where access to clinics for routine blood tests presents financial and logistical obstacles, HIV patients are increasingly able to collect and send a drop of blood using paper-based devices... Read moreMolecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more